116 filings
Page 3 of 6
8-K
xla49j77a uwx
4 Aug 21
Entry into a Material Definitive Agreement
12:00am
8-K
yhhsgeyjd
7 Jun 21
Submission of Matters to a Vote of Security Holders
4:35pm
8-K
w7m 20d8n
10 May 21
Cara Therapeutics Reports First Quarter 2021 Financial Results
4:10pm
8-K
5pt1 oxkm
29 Apr 21
Cara Therapeutics Announces Topline Results From
7:21am
8-K
nbp8d 797gpwzm4zma0
30 Mar 21
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
6:01am
8-K
b3pth0jalgop0ie
8 Mar 21
Regulation FD Disclosure
8:38am
8-K
ey5b9u2kxmslfvz so
25 Feb 21
Cara Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
4:10pm
8-K
l3jxm50p3ldn5
28 Dec 20
Regulation FD Disclosure
8:35am
8-K
gkt908jpm048gt t04v
9 Nov 20
Cara Therapeutics Reports Third Quarter 2020 Financial Results
4:10pm
8-K
ntjlcs10dz
20 Oct 20
Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus
6:30am
8-K
fzcis2
1 Oct 20
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
5:17pm
8-K/A
bolm742zy0
11 Aug 20
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
pbx 6iiz6q7v5m
10 Aug 20
Cara Therapeutics Reports Second Quarter 2020 Financial Results
4:10pm
8-K
6io93j
30 Jun 20
Departure of Directors or Certain Officers
7:18am
8-K
dryxcft019
17 Jun 20
Cara Therapeutics Announces Completion of Interim Statistical Assessment for KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with KARE Phase 2 Trial Design
7:11am
8-K
z7h91yh1rvzc4131i
5 Jun 20
Submission of Matters to a Vote of Security Holders
5:01pm
8-K
e7puzkk70ezbm4
11 May 20
Cara Therapeutics Reports First Quarter 2020 Financial Results
4:10pm
8-K
2r76r
21 Apr 20
Pharma Announce Positive Results From Global KALM-2
7:41am
8-K
9xyvsj
25 Mar 20
Cara Therapeutics Reports Clinical Updates
7:43am
8-K
7bxct
27 Feb 20
Cara Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
4:10pm